DJIA 17,387.21 -291.49 -1.65%
NASDAQ 4,681.50 -90.27 -1.89%
S&P 500 2,029.55 -27.54 -1.34%
market minute promo


company name or ticker

Others Overlooked VIVUS (VVUS), Should You Buy It Now? - Tale of the Tape

This Growing Concern Accounts For Nearly 500,000 Cancer Cases Each Year

A recent World Health Organization study shows that this growing problem is responsible for nearly a half-million cancer diagnoses each year.

Will Diabetes Drugs Enter The Anti-Obesity Space?

Could This Company Follow in Dendreon's Footsteps?

Dendreon's fall from grace wasn't pretty, and another once highly regarded biotech may eventually follow suit.

Why Orexigen Therapeutics, Inc. Stock Rocketed 43% Higher in November

Orexigen Therapeutics is the best biotech stock in November after its earnings report highlights progress with its Contrave program overseas.

Belviq Approaches 10,000 Ads Aired

Arena Pharmaceuticals: Belviq Sales Take A Modest Dip With Holiday

Why VIVUS (VVUS) Might Be a Diamond in the Rough - Tale of the Tape

Janssen Is Working Its Way Toward Anti-Obesity

EnteroMedics May Enter The Obesity Space - What Does It Mean?

See More Articles...